Akebia Therapeutics (AKBA) Revenue Growth (3y) (2020 - 2026)
Akebia Therapeutics (AKBA) Revenue Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.24 Bn | 87.37 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | 2.84% |
| 3 | Zoetis | 32.51 Bn | 30.56 Bn | 1.62 Bn | 4.19% |
| 4 | Takeda Pharmaceutical | 27.58 Bn | 23.52 Bn | 4.39 Bn | -4.46% |
| 5 | United Therapeutics | 23.18 Bn | 21.02 Bn | 648.10 Mn | 15.52% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | -2.00% |
| 8 | Neurocrine Biosciences | 17.94 Bn | 16.63 Bn | 800.70 Mn | 24.66% |
| 9 | Elanco Animal Health | 12.73 Bn | 12.30 Bn | 785.00 Mn | 2.94% |
| 10 | Akebia Therapeutics | 343.16 Mn | 180.56 Mn | 41.25 Mn | 10.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.20% |
| Dec 31, 2025 | 1.09% |
| Sep 30, 2025 | 6.45% |
| Jun 30, 2025 | -20.93% |
| Mar 31, 2025 | 810.34% |
| Dec 31, 2024 | 32.11% |
| Sep 30, 2024 | -8.44% |
| Jun 30, 2024 | -6.21% |
| Mar 31, 2024 | -14.57% |
| Dec 31, 2023 | 36.50% |
| Sep 30, 2023 | 41.00% |
| Jun 30, 2023 | -14.48% |
| Mar 31, 2023 | -23.25% |
| Dec 31, 2022 | 24.49% |
| Sep 30, 2022 | 69.52% |
| Jun 30, 2022 | 63.17% |
| Mar 31, 2022 | -88.47% |
| Dec 31, 2021 | -69.48% |
| Sep 30, 2021 | -2.85% |
| Jun 30, 2021 | 129.11% |